The North Shore University Hospital CCOP Program will utilize the comprehensive diagnostic and therapeutic facilities of a university-affiliated hospital to assist practicing community physicians. Full-time and voluntary staff oncologists with expertise in all modalities of cancer care will participate in clinical trials. Optimal protocol therapy will be provided by the Research Bases, Memorial Sloan-Kettering Cancer Center and Cancer and Leukemia Group B. Patients from a large catchment area of Long Island including Nassau County, eastern Queens County and western Suffolk County with a combined population over 3.4 million will be serviced.
The specific aim of this program will be to provide comprehensive cancer care for patients in all stages of disease which allows them to remain in their own comunity while receiving treatment. By increasing patient accrual on protocols, information about the effectiveness of their apeutic regimens in randomized studies can be rapidly obtained. New cancer chemotherapeutic agents can also be introduced and studied in the community setting. The CCOP administration will be located in North Shore University Hospital and consists of the Principal Investigator, Project Co-ordinator, Nurse Oncologist/Data Manager and Secretary. The CCOP components will include community physicians in groups or in single offices. The physicians will enter patients into protocols by contacting the CCOP administration which is responsible for entering appropriate data. Flow sheets will be forwarded to the Research Bases which will be responsible for data analysis, statistical support, education in data management and insuring quality control of treatment modalities and records. The overall impact of this program will be to introduce and maintain optimal therapy and reduced mortality for cancer patients whether or not they are entered into protocol treatment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035279-03
Application #
3557700
Study Section
(SRC)
Project Start
1983-09-01
Project End
1987-05-31
Budget Start
1985-09-01
Budget End
1987-05-31
Support Year
3
Fiscal Year
1985
Total Cost
Indirect Cost
Name
North Shore University Hospital
Department
Type
DUNS #
City
Manhasset
State
NY
Country
United States
Zip Code
11030
Vasu, Sumithira; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. Blood Adv 2:1645-1650
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. Leukemia 32:2536-2545
Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58
Kimmick, Gretchen G; Major, Brittny; Clapp, Jonathan et al. (2017) Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503). Breast Cancer Res Treat 163:391-398
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Uy, Geoffrey L; Mandrekar, Sumithra J; Laumann, Kristina et al. (2017) A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv 1:331-340
Eisfeld, A-K; Mrózek, K; Kohlschmidt, J et al. (2017) The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia. Leukemia 31:2211-2218
Phillips, Kelly-Anne; Regan, Meredith M; Ribi, Karin et al. (2016) Adjuvant ovarian function suppression and cognitive function in women with breast cancer. Br J Cancer 114:956-64
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9
Beumer, Jan H; Owzar, Kouros; Lewis, Lionel D et al. (2014) Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol 74:927-38

Showing the most recent 10 out of 111 publications